Hachinski
VC, Potter
P, Merskey
H. Leuko-araiosis. Arch Neurol. 1987;;44:21-- 23.
Pantoni
L, Garcia
JH. Pathogenesis of leukoaraiosis: a review. Stroke. 1997;;28:652-- 659.
Inzitari
D, Diaz
F, Fox
A.
et al. Vascular risk factors and leuko-araiosis. Arch Neurol. 1987;;44:42-- 47.
Scheltens
P, Barkhof
F, Valk
J.
et al. White matter lesions on magnetic resonance imaging in clinically diagnosed Alzheimer's disease: evidence for heterogeneity. Brain. 1992;;115:735-- 748.
Stout
JC, Jernigan
TL, Archibald
SL, Salmon
DP. Association of dementia severity with cortical gray matter and abnormal white matter volumes in dementia of the Alzheimer type. Arch Neurol. 1996;;53:742-- 749.
Skoog
I, Berg
S, Johansson
B, Palmertz
B, Andreasson
LA. The influence of white matter lesions on neuropsychological functioning in demented and non-demented 85-year-olds. Acta Neurol Scand. 1996;;93:142-- 148.
Claus
JJ, Breteler
MM, Hasan
D.
et al. Vascular risk factors, atherosclerosis, cerebral white matter lesions and cerebral perfusion in a population-based study. Eur J Nucl Med. 1996;;23:675-- 682.
Skoog
I. A review on blood pressure and ischaemic white matter lesions. Dement Geriatr Cogn Disord. 1998;;9:13-- 19.
Diaz-Arrastia
R. Hyperhomocysteinemia: a new risk factor for Alzheimer disease [editorial]. Arch Neurol. 1998;;55:1407-- 1408.
Sander
D, Winbeck
K, Klingelhofer
J, Conrad
B. Extent of cerebral white matter lesions is related to changes of circadian blood pressure rhythmicity. Arch Neurol. 2000;;57:1302-- 1307.
Merino
JG, Hachinski
V. Leukoaraiosis: reifying rarefaction [editorial]. Arch Neurol. 2000;;57:925-- 926.
Diaz-Arrastia
R. Homocysteine and neurologic disease. Arch Neurol. 2000;;57:1422-- 1428.
Clarke
R, Smith
AD, Jobst
KA, Refsum
H, Sutton
L, Ueland
PM. Folate, vitamin B12 and serum homocysteine levels in confirmed Alzheimer disease. Arch Neurol. 1998;;55:1449-- 1455.
McCaddon
AG, Davies
G, Hudson
P, Tandy
S, Cattell
H. Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry. 1998;;13:235-- 239.
McCaddon
A. Nutritionally independent B12 deficiency and Alzheimer disease [letter]. Arch Neurol. 2000;;57:607-- 608.
Lehmann
M, Gottfries
CG, Regland
B. Identification of cognitive impairment in the elderly: homocysteine is an early marker. Dement Geriatr Cogn Disord. 1999;;10:12-- 20.
Selhub
J, Bagley
LC, Miller
J, Rosenberg
IH. B vitamins, homocysteine, and neurocognitive function in the elderly. Am J Clin Nutr. 2000;;71(suppl):614S-- 620S.
Blennow
K, Wallin
A, Uhlemann
C, Gottfries
CG. White-matter lesions on CT in Alzheimer patients: relation to clinical symptomatology and vascular factors. Acta Neurol Scand. 1991;;83:187-- 193.
Rezek
DL, Morris
JC, Fulling
KH, Gado
MH. Periventricular white matter lucencies in senile dementia of the Alzheimer type and in normal aging. Neurology. 1987;;37:1365-- 1368.
Raiha
I, Tarvonen
S, Kurki
T, Rajala
T, Sourander
L. Relationship between vascular factors and white matter low attenuation of the brain. Acta Neurol Scand. 1993;;87:286-- 289.
Clarke
R, Joachim
C, Esiri
M.
et al. Leukoaraiosis at presentation and disease progression during follow-up in histologically confirmed cases of dementia. Ann N Y Acad Sci. 2000;;903:497-- 500.
Skoog
I. Status of risk factors for vascular dementia. Neuroepidemiology. 1998;;17:2-- 9.
Roth
M, Huppert
FA, Tym
E, Mountjoy
CQ. CAMDEX: The Cambridge Examination for Mental Disorders of the Elderly. Cambridge, England: Cambridge University Press; 1988;.
McKhann
G, Drachman
D, Folstein
M, Katzman
R, Price
D, Stadlan
EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;;34:939-- 944.
Mirra
SS, Heyman
A, McKeel
D.
et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), II: standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;;41:479-- 486.
Hogervorst
E, Barnetson
L, Jobst
KA, Nagy
Z, Combrinck
M, Smith
AD. Diagnosing dementia: interrater-reliability assessment and accuracy of the NINCDS/ADRDA criteria versus CERAD histopathological criteria for Alzheimer's disease. Dement Geriatr Cogn Disord. 2000;;11:107-- 113.
Mendes Ribeiro
HK, Barnetson
LPD, Hogervorst
E, Molyneux
AJ. A new visual rating scale for white matter low attenuation on CT. Eur Neurol. 2001;;45:140-- 144.
Refsum
H, Ueland
PM, Svardal
AM. Fully automated fluorescence assay for determining total homocysteine in plasma. Clin Chem. 1989;;35:1921-- 1927.
Nexo
E, Engbaek
F, Ueland
PM.
et al. Evaluation of novel assays in clinical chemistry: quantification of plasma total homocysteine. Clin Chem. 2000;;46:1150-- 1156.
Wenham
PR, Price
WH, Blundell
G. Apolipoprotein E genotyping by one-stage PCR. Lancet. 1991;;337:1158-- 1159.
de Groot
JC, de Leeuw
FE, Oudkerk
M.
et al. Cerebral white matter lesions and cognitive function: the Rotterdam Scan Study. Ann Neurol. 2000;;47:145-- 151.
Kanani
PM, Sinkey
CA, Browning
RL, Allaman
M, Knapp
HR, Haynes
WG. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation. 1999;;100:1161-- 1168.
Fassbender
K, Mielke
O, Bertsch
T, Nafe
B, Froschen
S, Hennerici
M. Homocysteine in cerebral macroangiography and microangiopathy [letter]. Lancet. 1999;;353:1586-- 1587.
Weir
DG, Scott
JM. Brain function in the elderly: role of vitamin B12 and folate. Br Med Bull. 1999;;55:669-- 682.
Lipton
SA, Kim
WK, Choi
YB.
et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci U S A. 1997;;94:5923-- 5928.
Wolf
R, Schabitz
FL, Fisher
M, Pak
HC. The N-methyl-D-aspartate antagonist CNS 1102 protects cerebral gray and white matter from ischemic injury following temporary focal ischemia in rats. Stroke. 2000;;31:1709-- 1714.
Barber
R, Gholkar
A, Scheltens
P, Ballard
C, McKeith
IG, O'Brien
JTO. MRI volumetric correlates of white matter lesions in dementia with Lewy bodies and AD. Int J Geriatr Psychiatry. 2000;;15:911-- 916.
Waldemar
G, Christiansen
P, Larsson
HBW.
et al. White matter magnetic resonance hyperintensities in dementia of the Alzheimer type: morphological and regional cerebral blood flow correlates. J Neurol Neurosurg Psychiatry. 1994;;57:1458-- 1465.
Doody
RS, Azher
SN, Haykal
HA, Dunn
JK, Liao
T, Schneider
L. Does APOE ϵ4 correlate with MRI changes in Alzheimer's disease? J Neurol Neurosurg Psychiatry. 2000;;69:668-- 671.
Hirono
N, Yasuda
M, Tanimukai
S, Kitagaki
H, Mori
E. Effect of apolipoprotein E ϵ4 allele on white matter hyperintensities in dementia. Stroke. 2000;;31:1263-- 1268.
Skoog
I, Hesse
C, Aevarsson
O.
et al. A population study of apoE genotype at the age of 85: relation to dementia, cerebrovascular disease, and mortality. J Neurol Neurosurg Psychiatry. 1998;;64:37-- 43.
Barber
R, Gholkar
A, Scheltens
P.
et al. Apolipoprotein E ϵ4 allele, temporal lobe atrophy, and white matter lesions in late-life dementias. Arch Neurol. 1999;;56:961-- 965.
Pasquier
F, Leys
D. Blood pressure and Alzheimer's disease. Rev Neurol. 1998;;154:743-- 751.
Skoog
I, Lernfelt
B, Landahl
S.
et al. 15-Year longitudinal study of blood pressure and dementia. Lancet. 1996;;347:1141-- 1145.
de Leeuw
F-E, de Groot
J-C, Achten
E.
et al. Prevalence of cerebral white matter lesions in elderly people. J Neurol Neurosurg Psychiatry. 2001;;70:9-- 14.
Tallova
J, Tomandl
J, Bicikova
M, Hill
M. Changes of plasma total homocysteine levels during the menstrual cycle. Eur J Clin Invest. 1999;;29:1041-- 1044.
Inzitari
D, Carlucci
G. White matter changes: the clinical consequences in the aging population. J Neural Transm Suppl. 2000;;59:1-- 8.
O'Brien
J, Perry
R. The association between white matter lesions on magnetic resonance imaging and noncognitive symptoms. Ann N Y Acad Sci. 2000;;903:482-- 489.
Wolf
H, Ecke
GM, Bettin
S, Dietrich
J, Gertz
HJ. Do white matter changes contribute to the subsequent development of dementia in patients with mild cognitive impairment? a longitudinal study. Int J Geriatr Psychiatry. 2000;;15:803-- 812.